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Noncirrhotic Portal
Hypertension and
Didanosine: A Re-Analysis
To the Editor—In 2020, Kovari et al
[1] reported a strong association between
exposure to didanosine (DDI) and non-
cirrhotic portal hypertension (NCPH),
a rare condition likely to be of multifacto-
rial etiology. However, the authors were
not able to control confounding through
multivariate modeling because of the
small number of case patients. This limi-
tation is typical of a rare condition,
making it more difficult to evaluate the
association of antiretroviral use with such
events because of the number of factors
that influence the prescription of these
drugs. With only 15 cases, adding even
a single confounder to a model may in-
troduce more bias than it removes because
of small sample bias away from the null
value (an odds ratio of 1) [2]. Their study
was, however, nested within the Swiss
HIV Cohort Study; thus, other methods of
confounder control are available. These
methods require additional modeling of
DDI use in the wider cohort.
Using logistic regression, we modeled
the probability of first use of DDI over
time for each patient in the cohort,
starting from the month when either
infection was first known or DDI was
first marketed in Switzerland until the
month of either first use of DDI or the
end of follow-up. Our model for first use
of DDI had a time-dependent intercept
based on a cubic spline and covariates of
sex, ethnicity, education, likely trans-
mission group, age, the number of failed
regimens (time dependent), and time-
dependent indicators for hepatitis
(chronic B or C), lipoatrophy, diabetes,
nervous system toxicity, Centers for
Disease Control and Prevention groups
B and C, use of zalcitabine, use of sta-
vudine, use of tenofovir, gastrointestinal
toxicity, and pregnancy and further in-
teraction terms between these last 4 in-
dicators and the time of related warnings
issued either by the US Food and Drug
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Administration or the drug company.
From this model, we then calculated
a propensity score for each patient at
each point in time: the probability of
exposure to DDI, given the patient’s
covariate and treatment history up to
that point. This probability is related to
an inverse probability of treatment
weight (IPTW) (see Appendix 1 in [3])
and can therefore be calculated in
a similar way (see Appendix in [4]).
We then re-analysed the original 15
case patients and 75 matched control
subjects, adjusting for a single covariate:
the propensity score at the date of di-
agnosis in the case patient. This means
that case and control exposures were
compared at a common value of the
propensity to be exposed to DDI. We
made this comparison at a common
value of the log-transformed propensity
score; with a log transformation, both
exposed and unexposed patients had
propensity scores with a similar vari-
ance, as is necessary for this method of
adjustment [5]. Finally, we added prior
information to our re-analysis. With
only a few matched sets, small sample
bias can be severe even when exposure is
the only variable in the model [6].
Adding prior information can limit this
bias by assigning essentially zero prior
probability to clinically implausible val-
ues of an estimate. One of us (MBK),
a clinician with expertise in liver disease
and HIV infection, having read other
case reports and series (see Table 1 in
[1]) and before reading about this study,
asserted her opinion that the odds of
NCPH in exposed patients, compared to
those unexposed, was a ratio of 1.2 per
year of exposure to DDI, with a 95%
confidence interval (CI) of .5–2.5. We
generated a set of matched case-control
pairs to represent this prior opinion and
then reran the analysis using both prior
and real data [7,8].
The published unadjusted odds ratio
for a year of exposure to DDI is 3.4
(95% CI, 1.5–8.1) [1]. After adjustment
using the log propensity score, our
estimate was 4.0 (95% CI, 1.2–13); a
weighted analysis using IPTWs gave an
estimate of 4.7 (95% CI, 1.4–16). In the
Bayesian analysis of prior and real data,
the adjusted estimate was 2.2 (95% CI,
1.5–3.3).
Propensity scores and IPTWs are ideal
methods of confounder control if the
outcome is rare but treatment is common
[9]. The 2 methods use very different
statistical logic; that both lead to a similar
estimate is reassuring. Propensity scores
have a Bayesian interpretation [5]; thus,
we used this method for our Bayesian
analysis. Our re-analysis showed how
even a large number of factors that po-
tentially influence treatment allocation
can be accounted for in the analysis of
a rare outcome. The strong association
between DDI and NCPH reported by
Kovari et al [1] does not appear to be an
artifact of inadequate confounder con-
trol. However, the published estimate is
probably an over-estimate to some de-
gree, because of small sample bias. That
said, there is sufficient evidence in these
data to convince a knowledgeable clini-
cian that the association may be of an
order of magnitude (of >2) to justify the
Food and Drug Administration warning
in January 2010 of an increased risk
of NCPH among patients exposed to
DDI [10].
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